Cargando…
苯达莫司汀单药治疗复发/难治B细胞非霍奇金淋巴瘤:一项前瞻、多中心、单臂、Ⅱ期临床研究
OBJECTIVE: To evaluate the efficacy and safety of bendamustine monotherapy in Chinese patients with relapsed/refractory(R/R)B cell non-Hodgkin lymphoma(B-NHL). METHODS: This prospective, multicenter, open label, single-arm, phase Ⅱ study investigated bendamustine's efficacy and safety in Chines...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808866/ https://www.ncbi.nlm.nih.gov/pubmed/36709185 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.11.009 |
Ejemplares similares
-
苯达莫司汀治疗B细胞性非霍奇金淋巴瘤的研究进展
Publicado: (2015) -
苯达莫司汀联合利妥昔单抗一线治疗惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤的真实世界研究
Publicado: (2023) -
苯达莫司汀联合利妥昔单抗治疗复发滤泡性淋巴瘤的临床分析
Publicado: (2022) -
Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析
Publicado: (2022) -
BTK抑制剂联合苯达莫司汀、利妥昔单抗一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效及安全性
Publicado: (2023)